In large clinical trials, full-dose anticoagulation (blood thinner) treatments given to moderately ill patients hospitalized for Covid-19 reduced the need for vital organ support, such as ventilation. A trend in reduced mortality was also observed and is under further study. With large numbers of Covid-19 patients requiring hospitalization, these outcomes could also help reduce the overload on intensive care units around the world.

NIH researchers report that a brain region in the superior temporal sulcus (fSTS) is crucial for processing and making decisions about visual information. The findings could provide clues to treating visual conditions from stroke.

Pregnant women who are infected with SARS-CoV-2, the virus that causes Covid-19, during the third trimester are unlikely to pass the infection to their newborns, suggests an NIH-funded study.

Psoriasis has long been known to increase the risk of cardiovascular disease, which includes heart attack and stroke. Now, researchers have identified a key culprit: the presence of metabolic syndrome (MetSyn).

Findings released in December from the most recent Monitoring the Future (MTF) survey of substance use behaviors and related attitudes among U.S. teens indicate that levels of nicotine and marijuana vaping did not increase from 2019 to early 2020, although they remain high.

Children who undergo cataract surgery as infants have a 22 percent risk of glaucoma 10 years later, whether or not they receive an intraocular lens implant. The findings come from the NEI-funded study.

The FDA recently granted emergency use authorization (EUA) for an innovative Covid-19 viral antigen test developed with technical support from NIH’s RADx Initiative, managed by NIBIB. The rapid, at-home test is available without a prescription.

Researchers at NEI have decoded brain maps of human color perception. The findings open a window into how color processing is organized in the brain, and how the brain recognizes and groups colors in the environment.

In a comprehensive analysis of patients with cancer who had exceptional responses to therapy, researchers have identified molecular changes in the patients’ tumors that may explain some of the exceptional responses. The results demonstrate that genomic characterizations of cancer can uncover genetic alterations that may contribute to unexpected and long-lasting responses to treatment.

Nearly two decades of NIH research helped lead to the first FDA-approved treatment for progeria, a rare and fatal pediatric disease, characterized by dramatic, rapid aging beginning in childhood. The new treatment was made possible thanks in part to the work of NHGRI researchers, led by NIH director and NHGRI senior investigator Dr. Francis Collins.